Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

Benzinga · 1d ago
Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.